BackgroundAirway microbiota composition has been clearly correlated with many pulmonary diseases, and notably with cystic fibrosis (CF), an autosomal genetic disorder caused by mutation in the CF tran
Targeted cystic fibrosis therapy with lumacaftor-ivacaftor is known to partially restore chloride channel function, improving epithelial fluid exchange, and consequently modifying microbiota and mycob
Introduction: Cystic fibrosis (CF) is a genetic disorder caused by mutations in the CFTR gene. A minority of people with CF carry two heterozygous CFTR mutations other than the common Phe508del, compl
